Sepracor - Journal Publications: XOPENEX® (levalbuterol)

1. Ozminkowski RJ, Wang S, Long SR. The impact of nebulized levalbuterol on health care payments for elderly asthma and chronic obstructive pulmonary disease patients in Medicaid plans. Dis Manage Health Outcomes 2007;15(1):41-55.

2006 XOPENEX (levalbuterol) Publications

1. Berger WE, Milgrom H, Skoner DP, Tripp K, Parsey MV, Baumgartner RA, Xopenex Pediatric Asthma Group. Evaluation of levalbuterol metered dose inhaler in pediatric patients with asthma: a double-blind, randomized, placebo- and active-controlled trial. CMRO 2006;22(6):1217-1226.

2. Chorley BN, Li Y, Fang S, Park JA, Adler KB. (R)-albuterol elicits antiinflammatory effects in human airway epithelial cells via iNOS. Am J Respir Cell Mol Biol 2006 January;34(1):119-27.

3. Donohue JF, Parsey, MV, Andrews C, D'Urzo T, Sharma S, Schaefer K, Claus R, Baumgartner RA, Levalbuterol COPD Study Group. Evaluation of the efficacy and safety of levalbuterol in subjects with COPD. COPD: The Journal of Chronic Obstructive Pulmonary Disease 2006; In press.

4. Harris MB, Lewis ER, Mazumder S, Akhmedov A, Factor P. Differential effects of r-, s- and rs-albuterol on alveolar epithelial cell b2-adrenergic receptor function and alveolar fluid clearance in miceb. Proceedings of the American Thoracic Society 2006;3:A762.

5. Ibe BO, Portugal AM, Raj JU. Levalbuterol inhibits human airway smooth muscle cell proliferation: therapeutic implications in the management of asthma. Int Arch Allergy Immunol 2006;139(3):225-236.

6. Nowak R, Emerman C, Hanrahan JP et al. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006 May;24(3):259-67.

7. O'Riordan TG, Mao W, Palmer LB, Chen JJ. Assessing the effects of racemic and single-enantiomer albuterol on airway secretions in long-term intubated patients. CHEST 2006 January;129(1):124-32.

2005 XOPENEX (levalbuterol) Publications

1. Ameredes BT, Calhoun WJ. Modulation of GM-CSF release by enantiomers of β-agonists in human airway smooth muscle. JACI 2005, 116(1):65-72.

2. Auais A, Wedde-Beer K, Piedimonte G. Anti-inflammatory effect of albuterol enantiomers during respiratory syncytial virus infection in rats. Pediatric Pulmonology 2005; 40(3):228-234.

3. Hardasmalani MD, DeBari V, Bithoney Wg, Gold N. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care 2005 July;21(7):415-419.

4. Qureshi F, Zaritsky A, Welch C, Meadows T, Burke BL. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med 2005: 46(1):29-36.

5. Ralston ME, Euwema MS, Knecht KR, Ziolkowski TJ, Coakley TA, Cline SM. Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial. J Emerg Med 2005 July;29(1):29-35.

6. Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med 2005 November;23(7):842-847.

7. Skoner DP, Greos LS, Kim KT, et al. Evaluation of the safety and efficacy of levalbuterol in 2-5-year-old patients with asthma. Pediatr Pulmonol 2005;40:477-486.